TPThierry Perez

Thierry Perez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thierry Perez has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and factors associated with exertional dyspnea in severe asthma: data at inclusion from the French RAMSES cohort

    by Jonathan Giovannelli, Thierry Perez, Gilles Garcia, Gilles Devouassoux, Stéphanie Fry, Arnaud Bourdin, Pascal Chanez, Philippe Bonniaud, Amel Boudjemaa, Christel Saint-Raymond, et al.

  • Electronic cigarette use and respiratory symptoms in the French population-based Constances cohort

    by Marie-Christine Delmas, Anne Pasquereau, Adeline Renuy, Laetitia Bénézet, Céline Ribet, Marie Zins, Romain Guignard, Thierry Pérez, Nicolas Roche, Bénédicte Leynaert


  • Dyspnea-induced Limitation (DYSLIM), a new self-administered concise questionnaire to evaluate dyspnea-related activity limitation in chronic respiratory diseases

    by Thierry Perez, Nicolas Roche, Hilario Nunes, Pierre-Régis Burgel, Ari Chaouat, Pascale Surpas, Frédéric Herengt, Gilles Garcia, Jean-Marie Grosbois, Sandrine Stelianides, et al.


  • Dyspnea-induced Limitation (DYSLIM), a self-administered questionnaire to evaluate dyspnea-related activity limitation in respiratory disease>

    by Thierry Perez, Nicolas Roche, Pierre Régis Burgel, Pascale Surpas, Ari Chaouat, Hilario Nunes, Frédéric Herengt, Jean Marie Grosbois, Gilles Garcia, Joel Coste

    Background and Aim: Few questionnaires are available for routine assessment of dyspnea with a sufficient responsiveness. Aim of study was to design a self-administered questionnaire assessing the impact of chronic dyspnea on daily activities. Methods: The development followed 3 steps: Step 1: selection of relevant activities and related questions (focus groups); step 2 (clinical study): internal and concurrent validity vs mMRC, Baseline Dyspnea Index (BDI) and Saint George Respiratory Questionnaire (SGRQ); step 3: item reduction. Initial version included 18 activities (from eating to climbing stairs) with 5 modalities for each: slowly, pauses, seeking assistance, changing habits, activity avoidance. Each modality was graded from 5 (never) to 1 (very often). Clinical study included 194 patients: COPD (FEV1 ≥ 50 % pred: n = 40 ; FEV1 < 50 % pred: n = 65); cystic fibrosis (n= 30), interstitial lung disease (n = 30), pulmonary hypertension (n= 29). Responsiveness was evaluated by post-pulmonary rehabilitation data in 52 COPD patients. Results: Acceptability was high and short term (7 days) reproducibility was satisfactory (Kappa ranging from 0.41 to 1). Concurrent validity was high vs mMRC (rho = 0.71), BDI (rho = - 0.75) and SGRQ (rho = - 0.79). The shortest reduced version with 7 activities (from washing to climbing stairs) and 3 modalities (slowly, seeking help, changing habits) showed similar validity. Regarding responsiveness, rehabilitation effect size was good for full (0.57) and reduced version (0.51). Conclusion: The Dyslim questionnaire appears promising for the evaluation of dyspnea induced limitation.

  • Open Access

    Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD

    by Maéva Zysman, Gaëtan Deslee, Thierry Perez, Pierre-Régis Burgel, Olivier Le Rouzic, Graziella Brinchault-Rabin, Pascale Nesme-Meyer, Isabelle Court-Fortune, Gilles Jebrak, Pascal Chanez, et al.

    Background: Chronic respiratory failure may occur as a consequence of chronic obstructive pulmonary disease (COPD) and is associated with significant morbidity and mortality. Hypoxemia is determined by underlying disease characteristics and comorbidities. Severe hypoxemia is typically only found in subjects with severe airflow obstruction (FEV1< 50% predicted). However, how hypoxemia relates to disease characteristics is not fully understood. Methods: In the French Initiatives BPCO real-life cohort, arterial blood gases were routinely collected in most patients. Relationships between severe hypoxemia, defined by a Pa02< 60 mmHg (8 kPa) and clinical/lung function features, comorbidities and mortality were assessed. In subjects with severe hypoxemia, clinical characteristics and comorbidities were compared between those with non-severe versus severe airflow limitation. Classification and regression trees (CART) were used to define clinically relevant subgroups (phenotypes). Results: Arterial blood gases were available from 887 subjects, of which 146 (16%) exhibited severe hypoxemia. Compared to subjects with a PaO2≥ 60 mmHg, the severe hypoxemia group exhibited higher mMRC dyspnea score, lower FEV1, higher RV and RV/TLC, more impaired quality of life, lower 6-minute walking distance, less frequent history of asthma, more frequent diabetes and higher 3-year mortality rate (14% versus 8%, p=0.026). Compared to subjects with Pa02< 60 mmHg and FEV1< 50% (n=115, 13%), those with severe hypoxemia but FEV1≥ 50% predicted (n=31) were older, had higher BMI, less hyperinflation, better quality of life and a higher rate of diabetes (29% versus 13%, p=0.02). Severe hypoxemia was better related to CART-defined phenotypes than to GOLD ABCD classification. Conclusion: In this cohort of stable COPD subjects, severe hypoxemia was associated with worse prognosis and more severe symptoms, airflow limitation and hyperinflation. Compared to subjects with severe hypoxemia and severe airflow limitation, subjects with severe hypoxemia despite non-severe airflow limitation were older, had higher BMI and more diagnosed diabetes. Trial Registration: 04– 479.


  • Open Access

    Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2

    by Arschang Valipour, Pallav L Shah, Felix J Herth, Christophe Pison, Christian Schumann, Ralf-Harto Hübner, Peter I Bonta, Romain Kessler, Wolfgang Gesierich, Kaid Darwiche, et al.

    Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization. Patients and Methods: TLD was performed in COPD patients (FEV1 30– 60% predicted, CAT≥ 10 or mMRC≥ 2) in a 1:1 randomized, sham-controlled, double-blinded multicenter study (AIRFLOW-2) using a novel lung denervation system (Nuvaira, Inc., USA). Subjects remained blinded until their 12.5-month follow-up visit when control subjects were offered the opportunity to undergo TLD. A time-to-first-event analysis on moderate and severe and severe exacerbations of COPD was performed. Results: Eighty-two subjects (FEV1 41.6± 7.4% predicted, 50.0% male, age 63.7± 6.8 yrs, 24% with prior year respiratory hospitalization) were randomized. Time-to-first severe COPD exacerbation was significantly lengthened in the TLD arm (p=0.04, HR=0.38) at 2 years post-TLD therapy and trended towards similar attenuation for moderate and severe COPD exacerbations (p=0.18, HR=0.71). No significant changes in lung function or SGRQ-C were found 2 years post randomization between groups. Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower risk of severe AECOPD over 2 years. Further, lung function and quality of life remained stable following TLD. Clinical Trial Registration: NCT02058459.


  • Open Access

    Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities

    by Thierry Perez, Gaëtan Deslée, Pierre Régis Burgel, Denis Caillaud, Olivier Le Rouzic, Maeva Zysman, Roger Escamilla, Gilles Jebrak, Pascal Chanez, Isabelle Court-Fortune, et al.

    Background: The 6-min walk test (6MWT) allows exercise tolerance to be assessed, and it has a significant prognostic value in COPD. The goal of this study was to analyse the determinants (obtained in routine practice) of a low 6-min walking distance (6MWD) and exercise-induced desaturation (EID) in COPD, including comorbidities. Methods: Patients were recruited from the real-life French COPD cohort “Initiatives BPCO”. A low 6MWD was defined as 2,), low BMI (BMI 2,), modified Medical Research Council (mMRC) dyspnea scale, FEV1% pred, FVC % pred, hyperinflation and comorbidities including cardiovascular diseases. Results: Among 440 patients with available 6MWT data, a 6MWD 2,=0.34), whereas no comorbidity was associated with a low 6WMD. EID was found in 155 patients (35%). This was positively associated with hypertension and negatively with age, obesity, FEV1% pred and resting SpO2 (rescaled r2,=0.37). Conclusion: 6MWD and EID exhibit different determinants in COPD with a minor impact of comorbidities limited to hypertension in EID and to obesity, which was unexpectedly associated with less EID. Other variables including age, routine resting lung function and SpO2 were weakly associated with 6MWD and EID. Altogether, these results suggest that 6MWT performance remains difficult to predict with routine clinical/functional parameters.


  • Open Access

    Prevalence and management of chronic breathlessness in COPD in a tertiary care center

    by on behalf of the Initiatives BPCO (bronchopneumopathie chronique obstructive) Scientific Committee and Investigators, H. Carette, M. Zysman, C. Morelot-Panzini, J. Perrin, E. Gomez, A. Guillaumot, P. R. Burgel, G. Deslee, P. Surpas, et al.

    Breathlessness is the prominent symptom of chronic obstructive pulmonary disease (COPD). Despite optimal therapeutic management including pharmacological and non-pharmacological interventions, many COPD patients exhibit significant breathlessness. Chronic breathlessness is defined as breathlessness that persists despite optimal treatment of the underlying disease. Because of the major disability related to chronic breathlessness, symptomatic treatments including opioids have been recommended by several authors. The prevalence of chronic breathlessness in COPD and its management in routine clinical practice have been poorly investigated. Our aim was to examine prevalence, associated characteristics and management of chronic breathlessness in patients with COPD recruited in a real-life tertiary hospital-based cohort. A prospective study was conducted among 120 consecutive COPD patients recruited, in stable condition, at Nancy University Hospital, France. In parallel, 88 pulmonologists of the same geographical region were asked to respond to an on-line questionnaire on breathlessness management. Sixty four (53%) patients had severe breathlessness (modified Medical Research Council scale≥3), despite optimal inhaled medications for 94% of them; 40% had undergone pulmonary rehabilitation within the past 2 years. The severity of breathlessness increased with increasing airflow limitation. Breathlessness was associated with increased symptoms of anxiety, depression and with osteoporosis. No relation was found with other symptoms, exacerbation rate, or cardiovascular comorbidities. Among the patients with chronic breathlessness and Hospitalized Anxiety and/or Depression score > 10, only 25% were treated with antidepressant or anxiolytic. Among the pulmonologists 46 (52%) answered to the questionnaire and expressed a high willingness to prescribe opioids forchronic breathlessness, which contrasted with the finding that none of these patients received such treatments against breathlessness. Treatment approaches to breathlessness and associated psychological distress are insufficient in COPD. This study highlights underuse of pulmonary rehabilitation and symptomatic treatment for breathlessness.


  • Open Access

    Factors associated with the 6-minute walk distance in patients with systemic sclerosis

    by Sébastien Sanges, Jonathan Giovannelli, Vincent Sobanski, Sandrine Morell-Dubois, Hélène Maillard, Marc Lambert, Céline Podevin, Nicolas Lamblin, Pascal De Groote, Jean-François Bervar, et al.

    There is an ongoing debate regarding the relevance of the 6-minute walking distance (6MWD) in systemic sclerosis (SSc) assessment, widely used as a usual test in these patients as well as an outcome measure in clinical trials. In this work, we aimed to assess the associations between the 6MWD and various disease parameters in patients with SSc. Consecutive patients followed in our SSc National Reference Centre were included in this cross-sectional study if they fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc. Data were systematically collected during a comprehensive standardized evaluation that included a 6-minute walk test, clinical assessment, biological results, pulmonary function tests, transthoracic echocardiography, composite scores (European Scleroderma Study Group Activity Index, Medsger severity score, Health Assessment Questionnaire–Disability Index (HAQ-DI)) and treatments. Associations of the 6MWD with various disease parameters were assessed by linear regression in univariate and multivariate analyses. The study population comprised 298 patients (females 81%; mean age 58.2 ± 13.3 years; limited cutaneous SSc 82%; interstitial lung disease (ILD) 42%; pulmonary arterial hypertension (PAH) 6%). The 6MWD was significantly and independently associated with gender, age, body mass index, baseline heart rate (HR), HR variation during the test, PAH, history of arterial thrombosis and C-reactive protein levels, as well as with the HAQ-DI score in a sensitivity analysis. Muscle involvement, joint involvement and ILD were not independently associated with the 6MWD. During SSc, the 6MWD is independently associated with initial HR and HR variation; with PAH but not ILD, suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation; and with global markers of disease activity and patient disability. These results give clinicians further insight into how to interpret the 6MWD in the context of SSc.


  • Open Access

    Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease

    by Pierre-Régis Burgel, Vincent Le Gros, Laurent Decuypère, Isabelle Bourdeix, Thierry Perez, Gaëtan Deslée

    The purpose of this study was to evaluate the correlation between immediate responsiveness with the short-acting β2-agonist salbutamol and effects of treatment with the ultra-long-acting β2-agonist indacaterol in patients with chronic obstructive pulmonary disease (COPD). The REVERBREZ study was a phase IV, multicentre, open-label study in which patients with moderate-to-severe COPD received indacaterol 150 μg once-daily for 5 months. The primary endpoint was the correlation between immediate response of forced expiratory volume in 1 s (FEV1) post-inhalation of salbutamol (400 μg) at study entry and the change from baseline in trough FEV1 after 1 month of indacaterol. Secondary endpoints included dyspnoea measured by the modified Medical Research Council (mMRC) grade and health-related quality of life measured by the clinical COPD questionnaire (CCQ). Of the 602 patients enrolled from 177 centres in France, 543 patients received at least one indacaterol dose, 512 patients completed 1 month of indacaterol treatment (primary endpoint), and 400 patients completed 5 months of treatment. At study entry, mean FEV1 values before and after salbutamol inhalation were 1.54 ± 0.50 L and 1.65 ± 0.53 L, respectively. Based on the magnitude of an immediate response of FEV1 after salbutamol inhalation at study entry, patients were classified into reversible (Rv, ≥12% and ≥200 mL from pre-salbutamol value; n = 106) and non-reversible (NRv, <12% or <200 mL from pre-salbutamol value; n = 431) groups. After 1 month of indacaterol treatment, mean absolute and relative difference in trough FEV1 were 100 mL and 9%, respectively. No significant correlation was found between the immediate FEV1 response to salbutamol at study entry and change from baseline in trough FEV1 after 1 month of indacaterol treatment (correlation coefficient = 0.056 [95% CI;−0.032, 0.144] for absolute response and 0.028 [95% CI;−0.06, 0.116] for relative response). At all subsequent visits, mMRC and CCQ scores, and FEV1 improved from baseline with no significant difference between the Rv and NRv groups. Immediate FEV1 response to salbutamol did not predict the long-term benefits observed with indacaterol treatment in patients with COPD. Patients considered reversible or non-reversible to salbutamol showed comparable improvements in lung function, dyspnoea and health-related quality of life. ClinicalTrials.gov: NCT01272362 . Date: January 5, 2011